DK174429B1 - Fast natriumnedocromil indeholdende bundet vand samt farmaceutisk præparat indeholdende det faste natriumnedocromil - Google Patents

Fast natriumnedocromil indeholdende bundet vand samt farmaceutisk præparat indeholdende det faste natriumnedocromil Download PDF

Info

Publication number: DK174429B1
Authority: DK; Denmark
Prior art keywords: sodium; sodium nedocromil; weight; nedocromil; solid sodium
Prior art date: 1984-04-13

Application number

DK198501609A

Other languages

Danish (da)

English (en)

Other versions

DK160985A (da

DK160985D0 (da

Inventor

Kenneth Brown

Andrew Reginald Clark

Richard Salliss

Original Assignee

Fisons Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-04-13

Filing date

1985-04-10

Publication date

2003-03-03

1984-04-13 Priority claimed from GB848409705A external-priority patent/GB8409705D0/en

1984-09-19 Priority claimed from GB848423634A external-priority patent/GB8423634D0/en

1985-04-10 Application filed by Fisons Plc filed Critical Fisons Plc

1985-04-10 Publication of DK160985D0 publication Critical patent/DK160985D0/da

1985-10-14 Publication of DK160985A publication Critical patent/DK160985A/da

2003-03-03 Application granted granted Critical

2003-03-03 Publication of DK174429B1 publication Critical patent/DK174429B1/da

Links

229910052708 sodium Inorganic materials 0.000 title claims description 71
239000011734 sodium Substances 0.000 title claims description 71
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims description 70
RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 title claims description 46
229960004398 nedocromil Drugs 0.000 title claims description 45
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 39
239000007787 solid Substances 0.000 title claims description 9
239000000825 pharmaceutical preparation Substances 0.000 title 1
239000000463 material Substances 0.000 claims description 30
239000000203 mixture Substances 0.000 claims description 27
239000003380 propellant Substances 0.000 claims description 17
239000007788 liquid Substances 0.000 claims description 13
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 11
235000019404 dichlorodifluoromethane Nutrition 0.000 claims description 11
239000002245 particle Substances 0.000 claims description 10
239000000843 powder Substances 0.000 claims description 10
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 5
239000004338 Dichlorodifluoromethane Substances 0.000 claims description 3
238000002329 infrared spectrum Methods 0.000 claims description 3
238000000634 powder X-ray diffraction Methods 0.000 claims description 3
UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 claims 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 36
239000002002 slurry Substances 0.000 description 17
239000002904 solvent Substances 0.000 description 15
238000000034 method Methods 0.000 description 14
230000001376 precipitating effect Effects 0.000 description 14
238000002360 preparation method Methods 0.000 description 12
239000000443 aerosol Substances 0.000 description 7
230000008569 process Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000013078 crystal Substances 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 5
239000008367 deionised water Substances 0.000 description 5
229910021641 deionized water Inorganic materials 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
238000002156 mixing Methods 0.000 description 5
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
-1 alkyl ketones Chemical class 0.000 description 4
238000009835 boiling Methods 0.000 description 4
230000008859 change Effects 0.000 description 4
238000001035 drying Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
239000004147 Sorbitan trioleate Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000003801 milling Methods 0.000 description 3
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
239000002736 nonionic surfactant Substances 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
235000019337 sorbitan trioleate Nutrition 0.000 description 3
229960000391 sorbitan trioleate Drugs 0.000 description 3
238000002411 thermogravimetry Methods 0.000 description 3
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229920004933 Terylene® Polymers 0.000 description 2
150000001335 aliphatic alkanes Chemical class 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
JQEKDNLKIVGXAU-UHFFFAOYSA-L nedocromil sodium Chemical compound [Na+].[Na+].CCN1C(C([O-])=O)=CC(=O)C2=C1C(CCC)=C1OC(C([O-])=O)=CC(=O)C1=C2 JQEKDNLKIVGXAU-UHFFFAOYSA-L 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
229940029284 trichlorofluoromethane Drugs 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
238000002083 X-ray spectrum Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000001273 butane Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
238000003921 particle size analysis Methods 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
229960005078 sorbitan sesquioleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK198501609A 1984-04-13 1985-04-10 Fast natriumnedocromil indeholdende bundet vand samt farmaceutisk præparat indeholdende det faste natriumnedocromil DK174429B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB848409705A GB8409705D0 (en)	1984-04-13	1984-04-13	Pharmaceutical formulation
GB8423634		1984-09-19
GB848423634A GB8423634D0 (en)	1984-09-19	1984-09-19	Pharmaceutical formulation
GB8409705		1984-09-19

Publications (3)

Publication Number	Publication Date
DK160985D0 DK160985D0 (da)	1985-04-10
DK160985A DK160985A (da)	1985-10-14
DK174429B1 true DK174429B1 (da)	2003-03-03

Family

ID=26287614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198501609A DK174429B1 (da)	1984-04-13	1985-04-10	Fast natriumnedocromil indeholdende bundet vand samt farmaceutisk præparat indeholdende det faste natriumnedocromil

Country Status (22)

Country	Link
US (2)	US4760072A (2)
EP (1)	EP0162556B1 (2)
JP (2)	JPH0613519B2 (2)
AU (1)	AU584329B2 (2)
BE (1)	BE902185A (2)
CA (1)	CA1257201A (2)
CH (1)	CH667271A5 (2)
DE (1)	DE3584580D1 (2)
DK (1)	DK174429B1 (2)
ES (1)	ES8800668A1 (2)
FI (1)	FI90942C (2)
FR (1)	FR2563105B1 (2)
GB (1)	GB2157291B (2)
GR (1)	GR850916B (2)
IE (1)	IE57653B1 (2)
IL (1)	IL74883A (2)
LU (1)	LU85850A1 (2)
MY (1)	MY100428A (2)
NO (1)	NO172542C (2)
NZ (1)	NZ211771A (2)
PT (1)	PT80275B (2)
SA (1)	SA94150322B1 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5260306A (en) *	1981-07-24	1993-11-09	Fisons Plc	Inhalation pharmaceuticals
DE3571439D1 (en) *	1984-01-26	1989-08-17	Fisons Plc	Benzopyran derivatives, compositions containing them and processes for their preparation
GB2187953B (en) *	1986-03-15	1989-11-15	Fisons Plc	Pharmaceutical formulation
DE3787274T2 (de) *	1986-12-23	1994-01-27	Fisons Plc	Pharmazeutische Präparate, die eine wässerige Lösung eines Pyranoquinolins enthalten.
USRE38628E1 (en) *	1986-12-23	2004-10-19	Fisons Plc	Pharmaceutical compositions
GB8704089D0 (en) *	1987-02-21	1987-03-25	Fisons Plc	Method of treatment
GB8704773D0 (en) *	1987-02-28	1987-04-01	Fisons Plc	Compounds
GB2202145B (en) *	1987-03-17	1991-01-02	Fisons Plc	Compositions of nedocromil for dermatological use.
GB8712251D0 (en) *	1987-05-23	1987-07-01	Fisons Plc	Formulation
GB8727590D0 (en) *	1987-11-25	1987-12-31	Fisons Plc	Formulation
GB8820267D0 (en) *	1988-08-26	1988-09-28	Fisons Plc	Pharmaceutical formulation
US5248493A (en) *	1988-08-27	1993-09-28	Fisons Plc	Pharmaceutical composition
GB8820398D0 (en) *	1988-08-27	1988-09-28	Fisons Plc	Pharmaceutical formulation
US5198221A (en) *	1989-05-17	1993-03-30	Fisons Plc	Pharmaceutical composition
GB8911259D0 (en) *	1989-05-17	1989-07-05	Fisons Plc	Inhalation medicament
US5195287A (en) *	1990-03-19	1993-03-23	Bemis Manufacturing Company	Panel and method of making the same
US6140348A (en) *	1997-09-19	2000-10-31	Auburn University	Treating/preventing heart failure via inhibition of mast cell degranulation
US5952353A (en) *	1997-09-19	1999-09-14	Auburn University	Treating/preventing heart failure via inhibition of mast cell degranulation
GB9806462D0 (en) *	1998-03-26	1998-05-27	Glaxo Group Ltd	Improved compositions for inhalation
AU2001283438A1 (en) *	2000-08-21	2002-03-04	Aeropharm Technology Incorporated	A method of stabilizing a dry powder pharmaceutical formulation
US20050026880A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
KR100550556B1 (ko) *	2003-11-11	2006-02-10	엘지전자 주식회사	에어컨의 중앙제어 시스템 및 그 동작방법
US9132116B2 (en)	2004-08-02	2015-09-15	Willowcroft Pharm Inc.	Mast cell stabilizers to prevent or treat laminitis
FR2898284B1 (fr) *	2006-03-10	2009-06-05	Inst Francais Du Petrole	Procede de desacidification d'un gaz par solution absorbante avec regeneration fractionnee par chauffage.
EP2137122A1 (en) *	2007-04-12	2009-12-30	Dow Global Technologies Inc.	Process and apparatus for reducing heavy byproduct formation during recovery of dichlorohydrins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA782473B (en) *	1977-05-04	1979-04-25	Fisons Ltd	Benzo pyrano-quinolinones
IL54614A (en) *	1977-05-04	1983-07-31	Fisons Ltd	Dihydrodioxo-pyranoquinoline dicarboxylic acid derivatives,their production and pharmaceutical compositions containing them
ZM8479A1 (en) *	1978-10-31	1980-09-22	Fisons Ltd	Compounds
FR2440371A1 (fr) *	1978-10-31	1980-05-30	Fisons Ltd	Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
DE3571439D1 (en) *	1984-01-26	1989-08-17	Fisons Plc	Benzopyran derivatives, compositions containing them and processes for their preparation

1985
- 1985-04-02 EP EP85302283A patent/EP0162556B1/en not_active Expired - Lifetime
- 1985-04-02 DE DE8585302283T patent/DE3584580D1/de not_active Expired - Lifetime
- 1985-04-03 GB GB08508782A patent/GB2157291B/en not_active Expired
- 1985-04-08 US US06/720,588 patent/US4760072A/en not_active Expired - Lifetime
- 1985-04-09 AU AU40942/85A patent/AU584329B2/en not_active Expired
- 1985-04-09 CA CA000478649A patent/CA1257201A/en not_active Expired
- 1985-04-10 FR FR8505380A patent/FR2563105B1/fr not_active Expired
- 1985-04-10 CH CH1532/85A patent/CH667271A5/fr not_active IP Right Cessation
- 1985-04-10 GR GR850916A patent/GR850916B/el not_active IP Right Cessation
- 1985-04-10 DK DK198501609A patent/DK174429B1/da not_active IP Right Cessation
- 1985-04-11 IL IL74883A patent/IL74883A/xx not_active IP Right Cessation
- 1985-04-12 JP JP60076904A patent/JPH0613519B2/ja not_active Expired - Lifetime
- 1985-04-12 ES ES542184A patent/ES8800668A1/es not_active Expired
- 1985-04-12 NZ NZ211771A patent/NZ211771A/xx unknown
- 1985-04-12 FI FI851463A patent/FI90942C/fi not_active IP Right Cessation
- 1985-04-12 IE IE938/85A patent/IE57653B1/en not_active IP Right Cessation
- 1985-04-12 BE BE0/214841A patent/BE902185A/fr not_active IP Right Cessation
- 1985-04-12 PT PT80275A patent/PT80275B/pt unknown
- 1985-04-12 LU LU85850A patent/LU85850A1/fr unknown
- 1985-04-12 NO NO85851475A patent/NO172542C/no not_active IP Right Cessation
1987
- 1987-07-25 MY MYPI87001128A patent/MY100428A/en unknown
- 1987-10-16 US US07/109,049 patent/US4918078A/en not_active Expired - Lifetime
1993
- 1993-07-21 JP JP5179507A patent/JPH0798749B2/ja not_active Expired - Lifetime
1994
- 1994-11-21 SA SA94150322A patent/SA94150322B1/ar unknown

Also Published As

Publication number	Publication date
FI851463L (fi)	1985-10-14
US4918078A (en)	1990-04-17
IE850938L (en)	1985-10-13
FI90942B (fi)	1994-01-14
LU85850A1 (fr)	1985-12-16
JPS60231680A (ja)	1985-11-18
AU4094285A (en)	1985-10-17
DE3584580D1 (de)	1991-12-12
US4760072A (en)	1988-07-26
NO172542B (no)	1993-04-26
FR2563105A1 (fr)	1985-10-25
PT80275B (pt)	1987-10-20
FI90942C (fi)	1994-04-25
IL74883A (en)	1990-08-31
FR2563105B1 (fr)	1987-02-13
DK160985A (da)	1985-10-14
SA94150322B1 (ar)	2004-08-31
DK160985D0 (da)	1985-04-10
AU584329B2 (en)	1989-05-25
ES8800668A1 (es)	1987-11-16
IE57653B1 (en)	1993-02-10
CH667271A5 (fr)	1988-09-30
NZ211771A (en)	1988-10-28
GR850916B (2)	1985-11-25
ES542184A0 (es)	1987-11-16
EP0162556A1 (en)	1985-11-27
MY100428A (en)	1990-09-29
NO172542C (no)	1993-08-04
NO851475L (no)	1985-10-14
JPH0613519B2 (ja)	1994-02-23
JPH0798749B2 (ja)	1995-10-25
CA1257201A (en)	1989-07-11
FI851463A0 (fi)	1985-04-12
GB8508782D0 (en)	1985-05-09
EP0162556B1 (en)	1991-11-06
JPH06227981A (ja)	1994-08-16
BE902185A (fr)	1985-07-31
GB2157291B (en)	1988-08-10
GB2157291A (en)	1985-10-23
PT80275A (en)	1985-05-01

Legal Events

Date	Code	Title	Description
1997-07-21	CTFF	Application for supplementary protection certificate (spc) filed	Free format text: CA 1997 00019, 970501
1997-10-13	CTFG	Supplementary protection certificate (spc) issued	Free format text: CA 1997 00019, 970501, EXPIRES: 20100212
2005-04-25	PUP	Patent expired

Publication	Publication Date	Title
US4918078A (en)	1990-04-17	Pharmaceutical Compositions containing nedocromil sodium
JP6857467B2 (ja)	2021-04-14	医薬品有効成分の粒子加工のための方法
Larhrib et al.	2003	The influence of carrier and drug morphology on drug delivery from dry powder formulations
DE2703119C2 (2)	1990-10-25
JPH04266872A (ja)	1992-09-22	複素環式化合物
US3300387A (en)	1967-01-24	Pressed powder antiperspirant and method of preparation
JP2008037812A (ja)	2008-02-21	化粧料組成物
KR20250019119A (ko)	2025-02-07	레티노산 알코올 아민계 복합물 및 그 제조 방법과 응용
HU226221B1 (en)	2008-06-30	Milling process for the production of finely milled medicinal substances
US5753208A (en)	1998-05-19	Antiasthmatic aerosol preparation of sodium cromoglycate
RU2203045C2 (ru)	2003-04-27	Способ получения фармацевтического состава
CN110115731A (zh)	2019-08-13	一种鲜地黄粉的制备方法及鲜地黄粉饮片
ME00247B (me)	2011-05-10	Formulacije hfa-suspenzija koje sadrže antiholinergik
GB2196254A (en)	1988-04-27	Nedocromil sodium formation
KR20040098049A (ko)	2004-11-18	흡입용 분말 제형
JPH04266815A (ja)	1992-09-22	封入アルミニウム塩組成物及びその製造方法
JPH0582365B2 (2)	1993-11-18
JPH02282330A (ja)	1990-11-19	ダナゾール組成物
AU2008285473A1 (en)	2009-02-12	Powdered medicament for nasal delivery of ascorbic acid for reducing apomorphine induced toxicity to ciliated tissue
BR102024004502A2 (pt)	2025-09-23	Processo de obtenção do extrato seco de hyptis pectinata (l.) kunt. e desenvolvimento de esponja para a cicatrização de feridas
NO126299B (2)	1973-01-22
JPS6411615B2 (2)	1989-02-27
JPS59110655A (ja)	1984-06-26	ｐ−ブトキシフェニルアセチルヒドロキサム酸の製造方法
CA2052193A1 (en)	1992-03-29	Topical powder composition containing cyclic amp derivative
US20080096970A1 (en)	2008-04-24	Stable Nateglinide Form B Compositions